Durvalumab Lengthens Survival in Extensive-Stage SCLC.
In the phase III CASPIAN trial, the PD-L1 inhibitor durvalumab plus standard chemotherapy outperformed chemotherapy alone, extending median overall survival in patients with extensive-stage small cell lung cancer.